FIELD: biotechnology.
SUBSTANCE: invention relates to new peptides containing epitopes recognized by CD4+ natural killer T(NKT)-cells, and may be used in medicine. An immunogenic fusion peptide binding CD1d and containing [FWHY]-xx-[ILMV]-xx-[FWHY] and [CST]-xx-C or C-xx-[CST] motifs.
EFFECT: invention allows to increase the activity of cells for use in case of infectious diseases, autoimmune diseases, immune reaction to allogeneic factors introduction, allergic diseases, for tumour therapy, for transplant rejection prevention and for prevention of immunization against viral proteins.
20 cl, 4 dwg, 8 ex
Authors
Dates
2017-04-04—Published
2011-11-24—Filed